Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals

NACompletedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

June 23, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

December 18, 2020

Conditions
Patient AdherenceHIV Seronegativity
Interventions
BEHAVIORAL

brief Motivational Interviewing

"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."

Trial Locations (5)

90027

Los Angeles Lesbian, Gay, Bisexual, and Transgender Center, Los Angeles

90033

University of Southern California, Los Angeles

90502

LA Biomed at Harbor-UCLA, Torrance

92103

Family Health Centers of San Diego, San Diego

University of California, San Diego, San Diego

All Listed Sponsors
collaborator

University of Southern California

OTHER

collaborator

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

collaborator

Los Angeles LGBT Center

OTHER

collaborator

Family Health Centers of San Diego

OTHER

lead

University of California, San Diego

OTHER

NCT03086200 - Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals | Biotech Hunter | Biotech Hunter